Press Releases
Pursuant to the Market Abuse Regulation, article 19, Svitzer Group A/S, CVR-no. 44 79 14 47, (“Svitzer Group” or the “Company”) hereby notifies receipt of information of the following transactions made by members of the Board of Directors or Executive Management in Svitzer Group or their closely associated persons in Svitzer Group’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S.
About Svitzer
Svitzer is a leading, global towage and... (continue reading...)
Restructuring of ownership in BW Energy Limited and exemption from the mandatory offer obligation
As previously disclosed, BW Group Limited ("BW Group") currently owns 191,903,110 shares in BW Energy Limited ("BW Energy"), corresponding to 74.38% of the issued and outstanding shares and voting rights in BW Energy.
As part of a corporate restructuring, BW Group is planning to separate BW Energy, as an oil & gas exploration business, from the maritime businesses held by... (continue reading...)
- XCE853 is Oregon Therapeutic’s first-in-class, and potentially best-in-class PDI inhibitor, exhibiting potent preclinical efficacy across multiple solid and hematological cancers, and is ready to advance to Investigational New Drug (IND)-enabling development.
- The AI-enabled collaboration aims to refine and expand the positioning of XCE853, a novel protein disulfide isomerase (PDI) inhibitor, in new and targeted oncology indications, including for drug-resistant... (continue reading...)
HONG KONG, May 6, 2024 /PRNewswire/ -- OKX Ventures, the investment arm of leading crypto exchange and Web3 technology company OKX, has announced a strategic investment in four consumer-oriented products from Web3 venture studio EVG. These include multi-chain SocialFi infrastructure Open Social Protocol, decentralized collaboration network Zeek, strategy card game Legend of Arcadia and real-time strategy game Last Odyssey.
WOODBURY, Minn. & ST. LOUIS--(BUSINESS WIRE)-- Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, today announced its investment in a second manufacturing line for the production of pressurized metered-dose inhaler (pMDI) products containing low-GWP (Global Warming Potential) propellants in its Loughborough, U.K., facility.
This new line will be capable of handling both HFA-152a and HFO-1234ze propellants — that have a GWP of... (continue reading...)
More Press Releases
View Older Stories-
SINOX Group to Showcase the Latest Synlox e-Security System at Eurobike
-
Rimsys Launches Community-Driven Regulatory Intelligence
-
SINOX Group to Showcase Universal Laptop Locks Aligning with the AI Era at Computex Taipei 2024
-
Oma Savings Bank Plc: Manager´s Transactions – Closely associated person Tanja Mäkynen
-
Oma Savings Bank Plc: Manager´s Transactions – Jyrki Mäkynen
-
Share buy-back programme - week 18
-
Elbit Systems Schedules First Quarter 2024 Results Release For May 28, 2024
-
INRED and SES to Provide High-Throughput Connectivity Across Colombia’s Amazonas
-
LHV Pank to contest the fine decision by Estonian Financial Intelligence Unit
-
Renault Group: Communication related to the availability of the EMTN base prospectus 2024
-
Transactions in connection with share buyback programme
-
Preliminary data on early redemptions (prepayments)
-
Pierre Anjolras appointed Chief Operating Officer of VINCI
-
Marimekko celebrates the 60th anniversary of the Unikko print in Helsinki and Tokyo with public open-air fashion shows
-
QUADIENT: 2024 Financial calendar - Update
-
Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
-
Exor Press Release - Periodic Report on the Buyback Program
-
Graphano Expands Zone 3 at LAB Graphite Project - Reports Remaining Program Results including 15.65 Metres Grading 7.91% Cg
-
KKR to Acquire Healthium from Apax Funds
-
TerraPay Continues to Attract Top Industry Talent, Names Hassan Chatila as Vice President and Global Head of Network
-
BrainChip and Frontgrade Gaisler to Augment Space-Grade Microprocessors with AI Capabilities
-
Xylem Unveils 'Reuse Brew'
-
SES to acquire Intelsat: Investor Relations Frequently Asked Questions
-
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
-
Health Canada Approves Nexstim NBS 6 System for Treatment of MDD
-
Aktsiaselts Infortar interim report for Q1 2024
-
Fingerprints and Infrafon collaborating on new smart badges for the European Medical and IoT market
-
Subsea7 share repurchases
-
M&P Receives a Specific License From the OFAC in Relation to Its Operations in Venezuela
-
Statement Concerning Eutelsat Group’s Ground Network
-
Ambri Agrees to Terms of Proposed Sale with Lender Consortium
-
BGHL (GBP): NAV(s)
-
BGHL (EUR): NAV(s)
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
Transaction in Own Shares
-
Declaration of shares and voting rights April 30, 2024 - VALNEVA SE
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
Start of Day Message
-
Market Update
-
Sohu.com to Report First Quarter 2024 Financial Results on May 20, 2024
-
CARMAT Continues to Build on Its Momentum in the EFICAS Study and Reiterates Confidence in Its 2024 Outlook
-
Elliptic Labs Shipping on vivo V30e Smartphone